PhoreMost and targeted protein degradation (TPD) specialists Arvinas have agreed a multi-target collaboration.
Under the terms of the agreement, PhoreMost will deploy its phenotypic screening platform, SITESEEKER, toward multiple high-value therapeutic targets. The output from SITESEEKER screening campaigns will be used to drive degrader drug discovery in oncology and neurodegeneration using Arvinas’s PROTAC Discovery Engine platform.
The platform is based on PhoreMost’s ‘Protein Interference’ (PROTEINi) technology, which probes the live cell environment for novel druggable targets linked to any chosen disease. SITESEEKER unmasks new druggable sites across the human proteome, linking them to useful therapeutic functions.
Dr Angela Cacace, Senior Vice President of Neuroscience & Platform Biology at Arvinas, said: “Identifying new protein binders is imperative for Arvinas as we expand the capabilities of our PROTAC platform. We are excited to begin this collaboration to leverage PhoreMost’s phenotypic screening platform and to make continued progress towards degrading undrugged targets across multiple complex diseases.”
